Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080771873> ?p ?o ?g. }
- W2080771873 abstract "Immunodeficient mice transplanted subcutaneously with human tumors (xenografts) are a widely used model of preclinical efficacy in the discovery and development of anti-cancer agents. We performed a retrospective population pharmacokinetic-pharmacodynamic (PK-PD) analysis of xenograft efficacy data that accounts for differences in clinical and preclinical drug exposure in order to improve their predictive value. In addition, we investigated the ability of xenograft studies to predict clinical response with newer molecular targeted agents. Data from preclinical and clinical studies with three cytotoxic chemotherapeutic agents (docetaxel, carboplatin, and 5-fluorouracil) and five molecular targeted agents (erlotinib, sunitnib, dasatinib, trastuzumab, and vismodegib) were included in this analysis. Anti-cancer agents were administered at a range of doses to xenograft mice bearing tumors relevant to the cancer of interest. No correlation was observed when comparing clinical response to % tumor growth inhibition (%TGI) at the maximum tolerated dose (MTD) in mice. PK-PD modeling was used to simulate %TGI in xenografts using human exposures at clinically relevant doses. These simulated %TGI in xenografts driven by human drug exposures were found to correlate (r=0.92; p=0.0005) with clinical response, illustrating the importance of taking into account species differences in drug exposure when interpreting xenograft data. Distinct differences were observed in the anti-tumor activity of sunitinib in Colo205 colorectal (simulated %TGI = 64%) and 786-O renal cell adenocarcinoma (simulated %TGI = 81%) xenografts, and vismodegib in medulloblastoma allografts (simulated %TGI =102%) and D5123 colorectal xenografts (simulated %TGI = 33%). These differences were consistent with the underlying biology of these models and demonstrate the importance of understanding tumor biology when selecting relevant xenograft models for molecular targeted agents. Based on these analyzes, agents that lead to greater than 60% tumor growth inhibition in preclinical models at clinically relevant exposures are more likely to lead to responses in the clinic. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr A11." @default.
- W2080771873 created "2016-06-24" @default.
- W2080771873 creator A5000331660 @default.
- W2080771873 creator A5005176422 @default.
- W2080771873 creator A5006218365 @default.
- W2080771873 creator A5027966349 @default.
- W2080771873 creator A5031820960 @default.
- W2080771873 creator A5032746475 @default.
- W2080771873 creator A5037737925 @default.
- W2080771873 creator A5055370060 @default.
- W2080771873 creator A5066658995 @default.
- W2080771873 creator A5068515055 @default.
- W2080771873 creator A5080833592 @default.
- W2080771873 date "2011-11-12" @default.
- W2080771873 modified "2023-09-25" @default.
- W2080771873 title "Abstract A11: Antitumor activity of targeted and cytotoxic agents in xenograft models correlates with clinical response: A pharmacokinetic-pharmacodynamic analysis." @default.
- W2080771873 doi "https://doi.org/10.1158/1535-7163.targ-11-a11" @default.
- W2080771873 hasPublicationYear "2011" @default.
- W2080771873 type Work @default.
- W2080771873 sameAs 2080771873 @default.
- W2080771873 citedByCount "2" @default.
- W2080771873 countsByYear W20807718732012 @default.
- W2080771873 crossrefType "proceedings-article" @default.
- W2080771873 hasAuthorship W2080771873A5000331660 @default.
- W2080771873 hasAuthorship W2080771873A5005176422 @default.
- W2080771873 hasAuthorship W2080771873A5006218365 @default.
- W2080771873 hasAuthorship W2080771873A5027966349 @default.
- W2080771873 hasAuthorship W2080771873A5031820960 @default.
- W2080771873 hasAuthorship W2080771873A5032746475 @default.
- W2080771873 hasAuthorship W2080771873A5037737925 @default.
- W2080771873 hasAuthorship W2080771873A5055370060 @default.
- W2080771873 hasAuthorship W2080771873A5066658995 @default.
- W2080771873 hasAuthorship W2080771873A5068515055 @default.
- W2080771873 hasAuthorship W2080771873A5080833592 @default.
- W2080771873 hasConcept C111113717 @default.
- W2080771873 hasConcept C112705442 @default.
- W2080771873 hasConcept C121608353 @default.
- W2080771873 hasConcept C126322002 @default.
- W2080771873 hasConcept C143998085 @default.
- W2080771873 hasConcept C2776694085 @default.
- W2080771873 hasConcept C2778239845 @default.
- W2080771873 hasConcept C2778804307 @default.
- W2080771873 hasConcept C2779490328 @default.
- W2080771873 hasConcept C2779545874 @default.
- W2080771873 hasConcept C2779786085 @default.
- W2080771873 hasConcept C2781190966 @default.
- W2080771873 hasConcept C2781451048 @default.
- W2080771873 hasConcept C2908647359 @default.
- W2080771873 hasConcept C3019992690 @default.
- W2080771873 hasConcept C526805850 @default.
- W2080771873 hasConcept C530470458 @default.
- W2080771873 hasConcept C71924100 @default.
- W2080771873 hasConcept C98274493 @default.
- W2080771873 hasConcept C99454951 @default.
- W2080771873 hasConceptScore W2080771873C111113717 @default.
- W2080771873 hasConceptScore W2080771873C112705442 @default.
- W2080771873 hasConceptScore W2080771873C121608353 @default.
- W2080771873 hasConceptScore W2080771873C126322002 @default.
- W2080771873 hasConceptScore W2080771873C143998085 @default.
- W2080771873 hasConceptScore W2080771873C2776694085 @default.
- W2080771873 hasConceptScore W2080771873C2778239845 @default.
- W2080771873 hasConceptScore W2080771873C2778804307 @default.
- W2080771873 hasConceptScore W2080771873C2779490328 @default.
- W2080771873 hasConceptScore W2080771873C2779545874 @default.
- W2080771873 hasConceptScore W2080771873C2779786085 @default.
- W2080771873 hasConceptScore W2080771873C2781190966 @default.
- W2080771873 hasConceptScore W2080771873C2781451048 @default.
- W2080771873 hasConceptScore W2080771873C2908647359 @default.
- W2080771873 hasConceptScore W2080771873C3019992690 @default.
- W2080771873 hasConceptScore W2080771873C526805850 @default.
- W2080771873 hasConceptScore W2080771873C530470458 @default.
- W2080771873 hasConceptScore W2080771873C71924100 @default.
- W2080771873 hasConceptScore W2080771873C98274493 @default.
- W2080771873 hasConceptScore W2080771873C99454951 @default.
- W2080771873 hasLocation W20807718731 @default.
- W2080771873 hasOpenAccess W2080771873 @default.
- W2080771873 hasPrimaryLocation W20807718731 @default.
- W2080771873 hasRelatedWork W1555190199 @default.
- W2080771873 hasRelatedWork W1997946609 @default.
- W2080771873 hasRelatedWork W2009058293 @default.
- W2080771873 hasRelatedWork W2020122374 @default.
- W2080771873 hasRelatedWork W2036746 @default.
- W2080771873 hasRelatedWork W2057494314 @default.
- W2080771873 hasRelatedWork W2063877253 @default.
- W2080771873 hasRelatedWork W2078276153 @default.
- W2080771873 hasRelatedWork W2087810891 @default.
- W2080771873 hasRelatedWork W2088047613 @default.
- W2080771873 hasRelatedWork W2104604857 @default.
- W2080771873 hasRelatedWork W2126953820 @default.
- W2080771873 hasRelatedWork W2247513204 @default.
- W2080771873 hasRelatedWork W2318451339 @default.
- W2080771873 hasRelatedWork W2319222851 @default.
- W2080771873 hasRelatedWork W2410266317 @default.
- W2080771873 hasRelatedWork W2413605623 @default.
- W2080771873 hasRelatedWork W2436525403 @default.
- W2080771873 hasRelatedWork W2471893399 @default.
- W2080771873 hasRelatedWork W2620678726 @default.
- W2080771873 isParatext "false" @default.
- W2080771873 isRetracted "false" @default.
- W2080771873 magId "2080771873" @default.